Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)
Нормализованный состав
fluticasone
salmeterol
COMPLETED
Первоисточник ↗
Информация
Изменилось с прошлой загрузки
Информация
Результаты не размещены (факт источника)
Информация
Связь с регистрацией не подтверждена
Факт источника
Основные сведения
- Компания / организация
- GlaxoSmithKline
- Протокол
- 100614
- Фаза
- PHASE4
- Статус
- COMPLETED
- Дата начала
- 31.01.2004
- Дата завершения
- 30.09.2005
- Участники
- 424
- Результаты
- Не найдены
Нормализация
Исходный и нормализованный состав
Факт источника
Salmeterol + fluticasone propionate
Значение сохранено без подмены исходного факта.
Нормализованное значение
fluticasone
salmeterol
Используется для поиска, сравнения и связывания.
Сопоставление
Связанные записи
История
Изменения относительно загрузок
details{'conditions': ['Asthma'], 'countries': ['South Korea'], 'interventions': [{'name': 'Salmeterol/ fluticasone propionate', 'type': 'DRUG', 'description': '2 active arms (parellel group)'}], 'sponsors': [{'name': 'GlaxoSmithKline', 'role': 'lead', 'agency_class': 'INDUSTRY'}], 'facilities': [{'zip': '431-070', 'city': 'Anyang-si', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Busan', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Jeonju', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Junjoo-Si', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Kyungki-Do Anyang-si', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Kyungki-Do', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '602-739', 'city': 'Pusan', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Pusan', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '120-752', 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '140-743', 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '152-703', 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}], 'outcomes': [], 'brief_summary': 'The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy compared to the current care in management of moderate to severe persistent asthma patients in Korea.', 'study_type': 'INTERVENTIONAL', 'source_organization': 'GlaxoSmithKline', 'results_first_posted_date': None, 'has_results_basis': 'results_first_posted_date'}→{'conditions': ['Asthma'], 'countries': ['South Korea'], 'interventions': [{'name': 'Salmeterol/ fluticasone propionate', 'type': 'DRUG', 'description': '2 active arms (parellel group)', 'other_names': ['SERETIDE'], 'design_groups': [{'id': 421724364, 'type': 'ACTIVE_COMPARATOR', 'title': 'Sal/FP 50/250mcg', 'description': 'SERETIDE 50/250'}, {'id': 421724365, 'type': 'ACTIVE_COMPARATOR', 'title': 'Sal/FP 50/500mcg', 'description': 'SERETIDE 50/500'}]}], 'composition_semantics': 'study_intervention_labels_not_product_formula', 'sponsors': [{'name': 'GlaxoSmithKline', 'role': 'lead', 'agency_class': 'INDUSTRY'}], 'facilities': [{'zip': '431-070', 'city': 'Anyang-si', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Busan', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Jeonju', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Junjoo-Si', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Kyungki-Do Anyang-si', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Kyungki-Do', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '602-739', 'city': 'Pusan', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Pusan', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '120-752', 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '140-743', 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': '152-703', 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}, {'zip': None, 'city': 'Seoul', 'name': 'GSK Investigational Site', 'state': None, 'country': 'South Korea'}], 'outcomes': [], 'brief_summary': 'The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy compared to the current care in management of moderate to severe persistent asthma patients in Korea.', 'study_type': 'INTERVENTIONAL', 'source_organization': 'GlaxoSmithKline', 'results_first_posted_date': None, 'has_results_basis': 'results_first_posted_date', 'start_date_type': None, 'start_month_year': '2004-01', 'start_date_precision': 'month', 'completion_date_type': 'ACTUAL', 'completion_month_year': '2005-09', 'completion_date_precision': 'month', 'primary_completion_date': '2005-09-30', 'primary_completion_month_year': '2005-09', 'primary_completion_date_precision': 'month', 'primary_completion_date_type': 'ACTUAL', 'intervention_component_groups': [['fluticasone', 'salmeterol']], 'intervention_normalization': [{'name': 'Salmeterol/ fluticasone propionate', 'selected_label': 'Salmeterol/ fluticasone propionate', 'selection_basis': 'primary_label', 'role': 'study_intervention', 'components': ['fluticasone', 'salmeterol'], 'unverified_label_components': [], 'items': [{'original': 'Salmeterol', 'component': 'salmeterol', 'status': 'resolved', 'method': 'versioned_lexicon'}, {'original': 'fluticasone propionate', 'component': 'fluticasone', 'status': 'resolved', 'method': 'versioned_lexicon'}], 'excluded_accessory_parts': [], 'verified_other_name_component_sets': []}]}